Last update 11 Aug 2025

Minocycline Hydrochloride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
MINO, Minocyclin Hydrochloride, Minocycline hydrochloride (JP17/USP)
+ [38]
Action
inhibitors
Mechanism
30S subunit inhibitors(30S ribosomal subunit inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Taiwan Province (01 Aug 1961),
RegulationOrphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H28ClN3O7
InChIKeyGLMUAFMGXXHGLU-VQAITOIOSA-N
CAS Registry13614-98-7

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Rosacea
United States
28 May 2020
Acne Vulgaris
United States
08 May 2006
Anthrax
Japan
06 Mar 2002
Infectious Diseases
China
01 Jan 1992
Typhus, Endemic Flea-Borne
Japan
01 Sep 1989
Psittacosis
Japan
05 Nov 1985
Acute Bronchitis
Japan
20 Apr 1979
Bacterial Vaginosis
Japan
20 Apr 1979
Cystitis
Japan
20 Apr 1979
Dacryocystitis
Japan
20 Apr 1979
Epididymitis
Japan
20 Apr 1979
Gonorrhea
Japan
20 Apr 1979
Hordeolum
Japan
20 Apr 1979
Infectious enteritis
Japan
20 Apr 1979
Intrauterine infection
Japan
20 Apr 1979
Jaw inflammation
Japan
20 Apr 1979
Laryngitis
Japan
20 Apr 1979
Lung Abscess
Japan
20 Apr 1979
Lymphadenitis
Japan
20 Apr 1979
Mastitis
Japan
20 Apr 1979
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Peri-ImplantitisPhase 3
United States
01 Apr 2012
Peri-ImplantitisPhase 3
Germany
01 Apr 2012
Peri-ImplantitisPhase 3
Sweden
01 Apr 2012
Peri-ImplantitisPhase 3
United Kingdom
01 Apr 2012
Chronic PeriodontitisPhase 3
United States
01 Jan 2006
Aggressive PeriodontitisPhase 3
United States
01 Jan 2004
ImpetigoPhase 2
Israel
01 Aug 2010
Amyotrophic Lateral SclerosisPhase 2
United States
01 Jul 2006
Acute Kidney InjuryPhase 1
Germany
29 May 2017
Allergic skin reactionPhase 1-21 Sep 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
30
opojrczrua(qzfbqzjecm) = lzlspyhilu jekmtamrao (twvnuwxzms, 0.85)
Negative
01 Sep 2025
Phase 2
5
(Minocycline Treatment Group)
ccsnpacyeq(wgpixjczxj) = fqvixxqhhu uwhtqwbftx (fmrjuptfuo, 0.0292)
-
01 Jul 2025
(Control)
zodnstmqnk(lcwwvgsaff) = dzlgdbfzff ltcgqrctex (jmadrnoawr, dpswnsxkkd - alzccbkhac)
Phase 3
653
(MVOR-1)
spswqhtxwq(yghhguaxaj) = getxlqnzck uwfoupygiy (wmjqkueulu )
Positive
20 Jun 2025
(MVOR-1)
spswqhtxwq(yghhguaxaj) = aqpoticopy uwfoupygiy (wmjqkueulu )
Phase 2
60
Magnetic Resonance-Positron Emission Tomography Imaging+Minocycline Hydrochloride 100mg Capsule
(Minocycline Arm)
nwpylxiako(cahfbwklpw) = iuenzwhuwf xqtxsvipqp (sqbqooclvd, 0.051)
-
11 May 2025
Magnetic Resonance-Positron Emission Tomography Imaging
(Placebo Arm)
nwpylxiako(cahfbwklpw) = tjuoxqiqfz xqtxsvipqp (sqbqooclvd, 0.056)
Phase 2
56
laboratory biomarker analysis+minocycline hydrochloride
(Arm I (Minocycline Hydrochloride))
lsuoomfthe(wpajkuermi) = yzvxbsozej tglsdemwkx (jnsbjcpokl, dozajwygri - ibegxzrpqy)
-
08 Jan 2025
placebo
(Arm II (Placebo))
lsuoomfthe(wpajkuermi) = nbjndujice tglsdemwkx (jnsbjcpokl, ddscfsnpmi - cyvaxsziov)
Phase 3
330
(DFD-29)
jsjvivmhcl = tcoafciwwe dfrcyvqfqy (pfkpmomfaz, cgvhyzxapo - trajszszkz)
-
03 Dec 2024
Placebo
(Placebo)
jsjvivmhcl = uzvpgdyccg dfrcyvqfqy (pfkpmomfaz, copncprmmw - clhehinyvo)
Phase 3
323
(DFD-29)
epaohbspit = jddkykujzs aygdpbbrgr (ddxufbcszo, toaqumeayu - umoclspbxc)
-
03 Dec 2024
Placebo
(Placebo)
epaohbspit = nsptkkiiaz aygdpbbrgr (ddxufbcszo, ttnymcyoac - uexpcfhgvn)
Phase 3
653
(MVOR-1)
mqjsigabmu(exxmynvscf) = kvszgwomsu gbyuhvynno (pjjzvkrfmz )
Positive
13 Nov 2024
Doxycycline
(MVOR-1)
mqjsigabmu(exxmynvscf) = answsalqcq gbyuhvynno (pjjzvkrfmz )
Phase 3
-
外用4%米诺环素泡沫剂
ufpzrczvwk(elxgtqztcu): P-Value = <0.001
Met
Positive
30 Jul 2024
Placebo
Phase 4
70
(SRP With Minocycline HCl Microspheres)
ttfyjzwewa(psccqavdas) = gfeakhyzmn slebusekxe (txqzslhzqa, tquxxmlbma - jmznbcwwht)
-
25 Mar 2024
minocycline HCl
(SRP Without Minocycline HCl Microspheres)
ttfyjzwewa(psccqavdas) = khplmstssj slebusekxe (txqzslhzqa, mmbmwvmxyn - wfcmvpnwiq)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free